Sector: Healthcare|Industry: Drug Manufacturers - Specialty & Generic|Market Cap: $11.52B|Employees: 18K
Catalent, Inc., together with its subsidiaries, develops and manufactures solutions for drugs, protein-based biologics, cell and gene therapies, and consumer health products worldwide. It operates in two segments, Biologics, and Pharma and Consumer Health. The Biologics segment provides formulation, development, and manufacturing for biologic proteins, cell gene, and other nucleic acid therapies; pDNA, iPSCs, oncolytic viruses, and vaccines; formulation, development, and manufacturing for parenteral dose forms, including vials, prefilled syringes, and cartridges; and analytical development and testing services for large molecules. The Pharma and Consumer Health segment offers formulation, development, and manufacturing services for soft capsules for use in a range of customer products, such as prescription drugs, over-the-counter medications, dietary supplements, unit-dose cosmetics, and animal health medicinal preparations; and oral, nasal, inhaled, and topical dose forms. This segment also provides clinical supply services through manufacturing, packaging, storage, distribution, and inventory management for small-molecule drugs, protein-based biologics, and cell and gene therapies in clinical trials; and pre-clinical screening, formulation, analytical development, and current good manufacturing practices manufacturing at clinical and commercial scale for softgel capsule, Zydis fast-dissolve tablets, oral solid-dose formats, dry powder inhalers, and nasal delivery devices. The company also offers FlexDirect direct-to-patient and FastChain demand-led clinical supply solutions; fill and finish operations for injectable products; and integrated development and product supply chain solutions. It serves biotechnology, pharmaceutical, and consumer health companies; and companies in other healthcare market segments, such as animal health and medical devices, as well as in cosmetics industries. The company was founded in 1933 and is headquartered in Somerset, New Jersey.
Catalent, Inc. is a global provider of development and manufacturing solutions for drugs, biologics, cell and gene therapies, vaccines, and consumer health products. The company operates approximately fifty facilities across four continents. Catalent's core business model involves helping customers bring products to market faster through its expertise in product development, regulatory compliance, and clinical and commercial supply. The company's market position is supported by its extensive capabilities, growth-enabling capacity, and deep industry know-how. Catalent serves a broad range of customers, including major pharmaceutical and biotechnology companies, and operates in key markets across North America, Europe, Asia Pacific, and South America. The company faces competition from other contract development and manufacturing organizations (CDMOs) and internal operations of its customers.
The executive leadership team has an average of approximately 29 years of functional experience.
Catalent offers a wide range of differentiated technologies, products, and services across its development and manufacturing platforms.
Catalent operates through two reportable segments:
Catalent's strategic ambition is to power innovation and growth in the life sciences industry by becoming a leading development and commercial partner. Key strategic initiatives include:
Catalent operates in the highly competitive pharmaceutical and biotechnology outsourcing market. Key market trends affecting the business include:
(Generated from latest 10-K filing)